Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin
for patients with unresectable, advanced gastric cancer who had no prior palliative
chemotherapy. Phase 1 was designed to determine the optimal dose of pemetrexed for its phase
2, which has been completed and now a total of 60 qualified patients will be enrolled in the
phase 2 of this study. The treating physician will determined the maximum number of cycles of
pemetrexed plus cisplatin that a patient may receive in this study.